1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 12,200 | 12,250 | 07.08. | |
| 12,100 | 12,300 | 07.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Bioventus Inc. Q2 Profit Advances | 2 | RTTNews | ||
| Mi | Bioventus Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| Mi | Bioventus Non-GAAP EPS of $0.22 in-line, revenue of $153.2M misses by $2.44M | 1 | Seeking Alpha | ||
| Mi | Bioventus Inc. - 8-K, Current Report | - | SEC Filings | ||
| Mi | Bioventus, Inc.: Bioventus Reports Second Quarter Financial Results | 191 | GlobeNewswire (Europe) | Q2 reported revenue of $153.2 million increased 4%Q2 GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted shareNon-GAAP earnings* of $0.22 per diluted... ► Artikel lesen | |
| BIOVENTUS Aktie jetzt für 0€ handeln | |||||
| 24.07. | Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect? | 1 | Zacks | ||
| 08.07. | Wall Street Analysts Predict a 28.81% Upside in Bioventus (BVS): Here's What You Should Know | 3 | Zacks | ||
| 07.07. | Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock? | 1 | Zacks | ||
| 23.06. | XFRA NEW INSTRUMENTS AVAILABLE ON 23.06.2026 | 388 | Xetra Newsboard | The following instruments on XETRA do have their first trading 23.06.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 23.06.2026
Aktien
1 CNE100007CW0 Shenzen Xunce Technology... ► Artikel lesen | |
| 04.06. | Bioventus Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.06. | Transcript: Bioventus Q1 2026 Earnings Conference Call | 1 | Benzinga.com | ||
| 29.05. | Bioventus (BVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now | 1 | Zacks | ||
| 21.05. | Bioventus Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.05. | Bioventus outlines 2026 adjusted EPS of $0.75-$0.79 while reaffirming $600M-$610M revenue | 1 | Seeking Alpha | ||
| 06.05. | Bioventus nach starkem Quartal: Gewinnprognose für 2026 angehoben | 5 | Investing.com Deutsch | ||
| 06.05. | Bioventus Q1 2026 slides: earnings beat drives guidance raise | 1 | Investing.com | ||
| 06.05. | Bioventus Non-GAAP EPS of $0.15 beats by $0.08, revenue of $132.1M beats by $2.2M | 2 | Seeking Alpha | ||
| 06.05. | Bioventus, Inc.: Bioventus Reports First Quarter Financial Results | 251 | GlobeNewswire (Europe) | Q1 reported revenue of $132.1 million increased 7%First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted shareNon-GAAP earnings* of $0.15... ► Artikel lesen | |
| 06.05. | Bioventus Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.05. | Bioventus Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 2,490 | -2,73 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,207 | +5,08 % | Viking Therapeutics, BioNxt Solutions, Bausch Health - Studienerfolg entfacht neue Fantasie | Die Pharmaindustrie steht vor einer neuen Wachstumsphase. Milliarden fließen in innovative Therapien, moderne Arzneimitteltechnologien und die Weiterentwicklung etablierter Medikamente. Besonders dynamisch... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,172 | +0,79 % | Biocryst outlines $690M-$715M 2026 total revenue guidance with operating costs at $420M-$440M | ||
| ARROWHEAD PHARMACEUTICALS | 74,84 | -1,29 % | Arrowhead plans sNDA by end of 2026 as SHASTA shows 79%-81% triglyceride reductions and 78% fewer pancreatitis events | ||
| ARBUTUS BIOPHARMA | 3,980 | -0,50 % | Arbutus, Genevant File International Lawsuits Against Pfizer, BioNTech | NEW YORK CITY (dpa-AFX) - Arbutus Biopharma (ABUS), and its licensee, Genevant Sciences - a unit of Roivant Sciences (ROIV)), announced the filing of three international lawsuits seeking to... ► Artikel lesen | |
| ATAIBECKLEY | 6,250 | -0,79 % | Laufende Fusionskontrollverfahren: Eli Lilly and Company, Indianapolis, IN/USA; Erwerb sämtlicher Anteile an und alleiniger Kontrolle über die AtaiBeckley Inc., New York/USA | Datum der Anmeldung:23.07.2026Aktenzeichen:B3-85/26Unternehmen:Eli Lilly and Company, Indianapolis, IN/USA; Erwerb sämtlicher Anteile an und alleiniger Kontrolle über die AtaiBeckley Inc., New York/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| ALDEYRA | 1,350 | 0,00 % | Aldeyra Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| ABCELLERA BIOLOGICS | 5,950 | -0,67 % | AbCellera rises as it will release phase 2 results of menopause asset | ||
| ADAPTIVE BIOTECHNOLOGIES | 21,370 | -0,84 % | Adaptive Biotechnologies Corp - 10-Q, Quarterly Report | ||
| BIOMERIEUX | 73,05 | 0,00 % | BioMerieux H1 Net Sales Slip On Foreign Exchange Impact; Backs Annual Sales Growth Outlook | PARIS (dpa-AFX) - BioMérieux SA (EYWN.MU, BIM.PA), a French biotechnology company, on Tuesday reported an increase in net income for the first half of fiscal 2026, helped by a drop in amortization... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,480 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| AC IMMUNE | 2,020 | -0,98 % | AC Immune SA: AC Immune First Half 2026 Financial and Corporate Update | AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances... ► Artikel lesen | |
| 10X GENOMICS | 44,700 | -0,80 % | 10x Genomics, Inc.: 10x Genomics Reports Second Quarter 2026 Financial Results | PLEASANTON, Calif., Aug. 6, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,780 | -1,02 % | BioXcel Therapeutics, Inc. - 8-K, Current Report | ||
| AGIOS | 27,800 | 0,00 % | Agios Pharmaceuticals, Inc.: Agios Reports Second Quarter 2026 Financial Results and Provides Business Update | Mitapivat (PYRUKYND and AQVESME) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025Strong U.S. commercial launch... ► Artikel lesen |
Das Unternehmen BIOVENTUS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,86 % bei einem Aktienkurs von 11,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOVENTUS INC finden Sie auf Wallstreet Online.